INCB7839 in Treating Children With Recurrent/Progressive High-Grade Gliomas

A Phase I Study of the Adam-10 Inhibitor, INCB7839 in Children With Recurrent/Progressive High-Grade Gliomas to Target Microenvironmental Neuroligin-3

This is a multicenter phase 1 trial of INCB7839 for children with recurrent or progressive high-grade gliomas, including, but not limited to, diffuse intrinsic pontine glioma (DIPG) and other diffuse midline gliomas (DMGs), after upfront therapy.

Study Overview

• Status: Active, not recruiting
• Conditions: Glioblastoma Multiforme; Anaplastic Astrocytoma; Anaplastic Oligodendroglioma; DIPG; High-grade Astrocytoma NOS; CNS Primary Tumor, NOS (Malignant Glioma)
• Intervention / Treatment: Drug: INCB7839

Detailed Description

INCB7839 is an inhibitor of the ADAM (A Disintegrin and Metalloprotease) 10 and 17 proteases. Neuronal activity regulates glioma growth through neuroligin-3 (NLGN3). ADAM 10 is the protease responsible for NLGN3 release into the tumor microenvironment and represents a promising therapeutic target.

Pre-clinical studies of INCB7839 in patient-derived pediatric high-grade gliomas (GBM and DIPG) revealed that INCB7839 inhibits pediatric high- grade glioma growth and improves overall survival. In vivo testing also demonstrated that INCB7839 penetrates brain tissue sufficient to achieve its pharmacodynamic effect of ADAM10 inhibition. Further pre-clinical studies in other animals revealed minimal toxicity, including non-adverse to mild increases in serum hepatobiliary enzymes, protein, calcium, cholesterol values, along with minimal decreases in RBC mass parameters; all parameters recovered.

INCB7839 has been evaluated in Phase I and Phase II clinical trials for previously treated solid tumors and breast cancer. Of the adverse events (AEs) noted, the majority were mild-to-moderate in severity, the most frequent being fatigue, nausea, anorexia, diarrhea, emesis, abdominal pain, anemia and constipation. The dose-limiting toxicity for monotherapy with INCB7839 in Phase I clinical trials was declared to be deep venous thrombosis (DVT). Out of 41 patients, there was a total of 9 thrombotic events including mild superficial thrombophlebitis (n=1), DVT (n=4), vena cava thrombosis with renal insufficiency in a patient with squamous cell cancer of the head and neck (n=1), atrial thrombosis in patient with breast cancer (n=1), and pulmonary embolism in patients with hormone-refractory prostate cancer (n=2). Overall, INCB7839 does exhibit a pro-coagulant effect in some adult patients, resulting in an increased incidence of DVT, whether used alone or in combination. The mechanism of this effect is unknown, and there is no clear relationship between the frequency of thrombosis and the dose administered.

• Study Type: Interventional
• Enrollment (Actual): 13
• Phase: Phase 1

Contacts and Locations

• Study Contact: Name: Nina Butingan, MBS; Phone Number: 901-671-6767; Email: nina.butingan@stjude.org

Study Locations

• United States
  • California
    • Los Angeles, California, United States, 90026
      • Children's Hospital Los Angeles
    • Palo Alto, California, United States, 94304
      • Stanford University and Lucile Packard Children's Hospital
  • Colorado
    • Aurora, Colorado, United States, 80045
      • Children's Hospital Colorado
  • District of Columbia
    • Washington, District of Columbia, United States, 20010
      • Children's National Medical Center
  • Illinois
    • Chicago, Illinois, United States, 60614
      • Ann & Robert H. Lurie Children's Hospital of Chicago
  • Massachusetts
    • Boston, Massachusetts, United States, 02245
      • Dana Farber Cancer Institute
  • New York
    • New York, New York, United States, 10065
      • Memorial Sloan Kettering Cancer Center
  • Ohio
    • Cincinnati, Ohio, United States, 45229
      • Cincinnati Children Hospital Medical Center
  • Pennsylvania
    • Pittsburgh, Pennsylvania, United States, 15224
      • Children Hospital of Pittsburgh
  • Tennessee
    • Memphis, Tennessee, United States, 38105
      • St. Jude Children's Research Hospital
  • Texas
    • Houston, Texas, United States, 77030
      • Texas Children's Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 3 years to 21 years (Child, Adult)
• Accepts Healthy Volunteers: No

Description

INCLUSION CRITERIA:

Histologic diagnosis:

• Patients with recurrent/progressive high-grade gliomas, as defined by progressive neurologic abnormalities or worsening neurologic status not explained by causes unrelated to tumor progression (e.g., anticonvulsant or corticosteroid wean, electrolyte disturbances, sepsis, hyperglycemia, etc.), OR a ≥ 25% increase in the bi-dimensional measurement, taking as a reference the smallest disease measurement recorded since diagnosis utilizing the MRI sequence best demonstrating tumor, OR the appearance of a new/metastatic tumor lesion(s) since diagnosis.
• Eligible diagnoses include but are not limited to the following: diffuse intrinsic pontine glioma (DIPG), H3K27M-altered diffuse midline glioma (DMG), glioblastoma multiforme, anaplastic astrocytoma and anaplastic oligodendroglioma. Spinal cord tumors are eligible with pathologic confirmation of the above.
• Please note: Patients with a radiographically typical DIPG at diagnosis, defined as a tumor with a pontine epicenter and diffuse involvement of more than 2/3 of the pons, are eligible without histologic confirmation.
• Patients with pontine lesions that do not meet these radiographic criteria will be eligible if there is histologic confirmation of pontine glioma WHO II-IV.
• Patients with diffuse or multi-focal disease are eligible; patients with leptomeningeal spread are eligible.

Age

• Patients must be ≥ 3 but ≤ 21 years of age at the time of enrollment.

BSA

• Patients must have a BSA ≥ 0.70-2.50 m2 for dose 120 mg/m2/dose BID.
• Patients must have a BSA ≥ 0.55-2.80 m2 for dose 80 mg/m2/dose BID (Patients who have BSA 0.55-1.00 m2 will only receive 100 mg AM dose).

Ability to Swallow

• Patients must be able to swallow tablets whole.

Measurable disease

• Patients must have measurable disease in two dimensions on MRI to be eligible.

Prior Therapy

• Patients must have failed at least 1 standard, tumor-directed treatment besides surgery and recovered from the acute treatment-related toxicities (defined as < Grade 1) of all prior chemotherapy, immunotherapy, or radiotherapy prior to enrollment on this study.

• Patients must be ≥ 28 days from any prior surgery at the time of study enrollment (with the exception of minor dental and dermatological procedures).

  • Chemotherapy

• Patients must have received their last dose of known myelosuppressive anticancer therapy at least 21 days prior to enrollment or at least 42 days if nitrosourea.

  • Investigational/ Biologic Agent
• Biologic or investigational agent (anti-neoplastic): Patients must have recovered from any acute toxicity potentially related to the agent and received their last dose of the investigational or biologic agent ≥ 7 days prior to study enrollment.
• For agents that have known adverse events occurring beyond 7 days after administration, this period must be extended beyond the time during which adverse events are known to occur.
• Monoclonal antibody treatment and agents with known prolonged half-lives: Patients must have recovered from any acute toxicity potentially related to the agent and received their last dose of the agent ≥ 28 days prior to study enrollment.

• Immunotherapies: Patients who have received checkpoint inhibitors or other immunotherapies with a known potential for pseudoprogression and who have assumed tumor progression must be at least 12 weeks from prior immunotherapy AND have at least two MRI scans at least 4 weeks apart demonstrating further progression OR have a biopsy to confirm tumor progression OR have new site(s) of disease.

  • Radiation

Patients must have had their last fraction of:

• Craniospinal irradiation, whole brain radiation, total body irradiation or radiation to ≥ 50% of pelvis or spine ≥ 42 days prior to enrollment.
• Focal irradiation ≥ 14 days prior to enrollment.
• Local palliative irradiation to site other than primary tumor progression site ≥ 14 days prior to enrollment.
• Stem Cell Transplant

Patients must be:

• ≥ 6 months since allogeneic stem cell transplant prior to enrollment with no evidence of active graft vs. host disease.
• ≥ 3 months since autologous stem cell transplant prior to enrollment.

Neurologic Status

• Patients with neurological deficits should have deficits that are stable for a minimum of 7 days prior to enrollment.
• Patients with seizure disorders may be enrolled if seizures are well controlled.

Performance Status

• Karnofsky Performance Scale (KPS for > 16 years of age) or Lansky Performance Score (LPS for ≤ 16 years of age) assessed within two weeks of enrollment must be ≥ 50.

Organ Function: Patients must have adequate organ and marrow function as defined below:

• Absolute neutrophil count ≥ 1.0 x 10^9 cells/ L
• Platelets > 100 x 10^9 cells/ L (unsupported, defined as no platelet transfusion within 7 days)
• Hemoglobin ≥ 8 g/dL (may receive transfusions)
• Total bilirubin ≤ 1.5 times institutional upper limit of normal (ULN)
• ALT (SGPT) and AST (SGOT) < 3 x institutional upper limit of normal (ULN)
• Albumin ≥ 2 g/dL
• Serum creatinine based on age/gender as noted in institutional normal range. Patients that are not within institutional normal range but have a 24-hour Creatinine Clearance or GFR (radioisotope or iothalamate) ≥ 70 mL/min/1.73 m^2 are eligible.

Corticosteroids

• Patients who are receiving dexamethasone must be on a stable or decreasing dose for at least 7 days prior to enrollment.

Growth Factors

• Patients must be off all colony-forming growth factor(s) for at least 7 days prior to enrollment (e.g., filgrastim, sargramostim or erythropoietin). Fourteen (14) days must have elapsed if patient received a long-acting formulation.

Pregnancy Prevention

• Patients of childbearing or child fathering potential must be willing to use a medically acceptable form of birth control, which includes abstinence, while being treated on this study.

Informed Consent

• The patient or parent/guardian is able to understand the consent and is willing to sign a written informed consent document according to institutional guidelines.

HIV Positive Patients

• HIV-positive patients are eligible if the following criteria are met:

  • Stable on their antiretroviral agents
  • Have CD4 counts above 400/mm^3
  • Undetectable viral loads, and
  • No need for prophylactic medications for an opportunistic infections

EXCLUSION CRITERIA:

Pregnancy or Breast-feeding

• Pregnant women or nursing mothers are excluded from this study. Female patients of childbearing potential must have a negative serum or urine pregnancy test within 72 hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.

  • Pregnant or breast-feeding women are excluded from this study due to risks of fetal and teratogenic adverse events as seen in animal studies.

Concurrent Illness

• Patients with any clinically significant unrelated systemic illness (e.g., serious infections or significant cardiac, pulmonary, hepatic or other organ dysfunction), that in the opinion of the investigator would compromise the patient's ability to tolerate protocol therapy, put them at additional risk for toxicity or would interfere with the study procedures or results.
• Patients with any other current malignancy.

• Patients with uncontrolled hypertension (i.e., a blood pressure (BP) > 95th percentile for age, height, and gender; patients with values above these levels must have their blood pressure controlled with medication prior to starting study drug).

  • The normal blood pressure by height, age, and gender tables can be accessed in the Generic Forms section of the PBTC member's webpage.
  • Patients who are ≥ 18 years of age must have blood pressure that is < 140/90 mm of Hg at the time of registration.

Concomitant Medications

• Patients who are receiving any other anti-cancer, investigational or alternative (e.g., cannabinoids) drug therapy are ineligible.

Prisoners

• Prisoners will be excluded from this study.

Inability to participate

• Patients who in the opinion of the investigator are unwilling or unable to return for required follow-up visits or obtain follow-up studies required to assess toxicity to therapy or to adhere to drug administration plan, other study procedures and study restrictions.

Allergy

• Patients with a history of allergic reactions attributed to compounds of similar chemical or biologic composition.
• Patients with a history of allergy to pork products due to contraindications with low molecular weight heparin (LMWH).

Thrombosis Risk

• Patients with a known coagulopathy or bleeding disorder (e.g., von Willebrands disease) are not eligible.
• Patients with a history of non-central line related thrombosis or disorders that promote clotting (e.g., anti-thrombin III deficiency, Lupus anticoagulant) are not eligible.
• Significant family history of thrombosis (i.e. deep venous thrombosis or pulmonary embolus) in a first-degree relatives (i.e., parents or siblings) are not eligible.
• Estrogen containing contraceptives are not permitted due to thrombotic risk. Progestin-only contraception along with alternate forms of contraception are acceptable.
• Patients should be counseled to avoid smoking/tobacco products.
• If there is any contraindication to DVT prophylaxis, the patient is not eligible.

Family history must be documented to the best extent it is known.

Subjects with current or prior symptomatic intratumoral or intracranial hemorrhage are ineligible.

Subjects with asymptomatic evidence of new CNS hemorrhage of more than punctate size (i.e., ≥ 4 mm) and/or more than one punctate focus of hemorrhage (< 4 mm or not seen on more than one slice) on baseline MRI obtained within 14 days prior to study enrollment are ineligible.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Experimental: Dose-finding; INCB7839 dosing will begin at 120 mg/m2/dose BID which is equivalent to the adult RP2D (200 mg PO BID) based on a typical adult size of 1.67m2. The INCB7839 dose may be decreased to 80 mg/m2/dose BID if the staring dose is not tolerable. 28 consecutive days (4 weeks) will constitute one course. Patients may continue to receive INCB7839 for 26 courses (approximately 2 years).

Drug: INCB7839; INCB7839 dosing will begin at 120 mg/m2/dose BID which is equivalent to the adult RP2D (200 mg PO BID) based on a typical adult size of 1.67m2. The INCB7839 dose may be decreased to 80 mg/m2/dose BID if the staring dose is not tolerable. 28 consecutive days (4 weeks) will constitute one course. Patients may continue to receive INCB7839 for 26 courses (approximately 2 years).

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
To evaluate the incidence of INCB7839 treatment-emergent adverse events in children with recurrent/progressive High-Grade Gliomas.	Number of participants with treatment-emergent adverse events as assessed by CTCAE v5.0.	Up to 30 days post treatment.
Maximum tolerated dose (MTD) and/or recommend Phase II dose (RP2D) of INCB7839.	To estimate the maximum tolerated dose (MTD) and/or recommend Phase II dose (RP2D) of INCB7839 administered orally in children with recurrent/progressive high-grade glioma.	Up to 30 days post treatment.
To characterize the area under the plasma concentration versus time curve (AUC) of INCB7839 administered on this schedule in children with recurrent/progressive high-grade glioma.	The area under the curve (AUC) will be calculated based on the course 1 days 1 and 2 pharmacokinetic samples.	Up to 3 days after the first dose in Course 1.
To characterize the maximum concentration [CMAX] of INCB7839 administered on this schedule in children with recurrent/progressive high-grade glioma.	The maximum concentration [CMAX] will be calculated based on the course 1 days 1 and 2 pharmacokinetic samples.	Up to 3 days after the first dose in Course 1.
To characterize the apparent oral clearance [CL/F] of INCB7839 administered on this schedule in children with recurrent/progressive high-grade glioma.	The apparent oral clearance [CL/F] will be calculated based on the course 1 days 1 and 2 pharmacokinetic samples.	Up to 3 days after the first dose in Course 1.
To characterize the time to reach CMAX [TMAX] of INCB7839 administered on this schedule in children with recurrent/progressive high-grade glioma.	The time to reach CMAX [TMAX] will be calculated based on the course 1 days 1 and 2 pharmacokinetic samples.	Up to 3 days after the first dose in Course 1.

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
To make a preliminary assessment of progression-free survival in children with recurrent/progressive high-grade glioma.	The progression-free survival will be reported.	Up to 2 years following last dose of INCB7839.
To make a preliminary assessment of overall survival in children with recurrent/progressive high-grade glioma.	The overall survival will be reported.	Up to 2 years following last dose of INCB7839.
To make a preliminary assessment of duration of response in children with recurrent/progressive high-grade glioma.	The duration of response will be reported.	Up to 2 years following last dose of INCB7839.

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
ADAM10 inhibition of HER2 extracellular domain in serum.	HER2 extracellular domain in serum will be reported.	Course 1 (up to 28 days after the first dose).
To assess and monitor ADAM10 inhibition of neuroligin-3 (NLGN3) in cerebral spinal fluid.	Neuroligin-3 (NLGN3) in cerebral spinal fluid will be reported.	Up to 30 days post treatment.
To characterize the maximum concentration [CMAX] of INCB7839 in cerebrospinal fluid.	The maximum concentration [CMAX] will be calculated based on the CSF pharmacokinetic samples.	Up to 30 days post treatment.

Collaborators and Investigators

• Sponsor: Pediatric Brain Tumor Consortium
• Collaborators: National Cancer Institute (NCI); American Lebanese Syrian Associated Charities (ALSAC)
• Investigators: Study Chair: Michelle Monje, MD, PhD, Stanford University and Lucile Packard Children's Hospital

Study record dates

Study Major Dates

• Study Start (Actual): July 27, 2020
• Primary Completion (Actual): December 31, 2023
• Study Completion (Estimated): June 30, 2024

Study Registration Dates

• First Submitted: February 27, 2020
• First Submitted That Met QC Criteria: March 2, 2020
• First Posted (Actual): March 4, 2020

Study Record Updates

• Last Update Posted (Actual): April 8, 2024
• Last Update Submitted That Met QC Criteria: April 5, 2024
• Last Verified: April 1, 2024

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Neoplasms by Histologic Type; Neoplasms; Neoplasms, Glandular and Epithelial; Neoplasms, Neuroepithelial; Neuroectodermal Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms, Nerve Tissue; Glioblastoma; Glioma; Astrocytoma; Oligodendroglioma
• Other Study ID Numbers: PBTC-056 (Other Identifier: CTEP); UM1CA081457 (U.S. NIH Grant/Contract); NCI-2019-08964 (Registry Identifier: CTRP (Clinical Trial Reporting Program))

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No